Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a virtual fireside chat at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit on Monday, September 19, 2022 at 12:05 PM Eastern Time.

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

Neurocrine Biosciences

Vertex Pharmaceuticals

These three biotech companies have bucked the trend of declining shares prices in their sector.

3 Growth Stocks That Are Crushing It This Year

Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.

Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study

Its near-term outlook is quite rosy, but there is also a risk it might not meet investors' hopes.

Is Axsome Therapeutics a Buy?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?

Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.

Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why

Upstart Holdings

These stocks are poised for a strong rebound once the ongoing bear market turns bullish again.

Nasdaq Bear Market: 2 Top Growth Stocks You'll Wish You'd Bought on the Dip

Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the EMERGE trial of AXS-07 for the acute treatment of migraine.

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Sarepta Therapeutics

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

Alnylam Pharmaceuticals

bluebird bio

Karuna Therapeutics Inc

Biotech stocks are scorching right now. But the best of the best have strong gains.

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others

Rhythm Pharmaceuticals

Shockwave Medical

Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals.

3 Healthcare Stocks That Are Beating the Market

It may not be too late to get in on this drugmaker.

This Growth Stock Is Soaring. Is It a Buy?

Wall Street is optimistic about the company's newly approved depression medication.

Why Axsome Therapeutics Stock Jumped This Week

The FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major depressive disorder in adults. This becomes the first approved product for the company.

Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity

These three biotech companies could be headed for a buyout soon.

3 Biopharmas on Buyout Watch

A long-delayed announcement from the FDA was even more positive than expected.

Does a New Depression Drug Make This Stock a Buy Now?

The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher. The post Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression Drug appeared first on Investor's Business Daily.

Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression Drug

the Food and Drug Administration approved Axsome Therapeutics anti-depression drug Auvelity which reduces symptions as early as one week.

Axsome's depression drug enters competitive market after US approval

The biotech's drug for major depressive disorder has been formally approved by the FDA.

Why Axsome Therapeutics Stock Is Crushing It Today

Shares of Axsome Therapeutics (NASDAQ: AXSM ) are up more than 30% today on news that the biopharmaceutical company has received approval from the U.S. Food and Drug Administration (FDA) for a unique, first-of-its-kind depression treatment. Specifically, the FDA has approved Axsome Therapeutics' new drug Auvelity, extended-release tablets that are used to treat major depressive disorders (MDD) in adults.

Why Is Axsome Therapeutics (AXSM) Stock Up 30% Today?

The U.S. Food and Drug Administration has approved Axsome Therapeutics Inc's oral depression pill, the company said on Friday, sending its shares soaring 38% in premarket trading.

Axsome surges after oral depression drug gets FDA approval

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week 1 -4

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

The company records nearly $9 million in quarterly sales from its recently acquired drug.

News for Axsome Therapeutics Stock (AXSM)